Astrazeneca PLC (AZN): Price and Financial Metrics

Astrazeneca PLC (AZN)

Today's Latest Price: $48.90 USD

0.38 (-0.77%)

Updated Jan 27 6:40pm

Add AZN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AZN Stock Summary

  • Astrazeneca Plc's market capitalization of $128,731,206,698 is ahead of 98.54% of US-listed equities.
  • Price to trailing twelve month operating cash flow for AZN is currently 33.6, higher than 88.07% of US stocks with positive operating cash flow.
  • As for revenue growth, note that AZN's revenue has grown -15.35% over the past 12 months; that beats the revenue growth of just 11.91% of US companies in our set.
  • Stocks that are quantitatively similar to AZN, based on their financial statements, market capitalization, and price volatility, are LLY, TXN, AMGN, PYPL, and SNY.
  • Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to
AZN Daily Price Range
AZN 52-Week Price Range

AZN Stock Price Chart More Charts

AZN Price/Volume Stats

Current price $48.90 52-week high $51.55
Prev. close $49.28 52-week low $35.30
Day low $48.61 Volume 2,265,500
Day high $49.07 Avg. volume 2,319,300
50-day MA $49.12 Dividend yield 1.8%
200-day MA $43.91 Market Cap 128.30B

Astrazeneca PLC (AZN) Company Bio

AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$48.90$4.43 -91%

Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 58th percentile in terms of potential gain offered. As for the metrics that stood out in our discounted cash flow analysis of Astrazeneca Plc, consider:

  • Its compound free cash flow growth rate, as measured over the past 3.99 years, is -0.23% -- higher than merely 8.46% of stocks in our DCF forecasting set.
  • As a business, AZN is generating more cash flow than 89.14% of positive cash flow stocks in the Healthcare.
  • Astrazeneca Plc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AZN, try BSX, ENSG, HAE, LCTC, and MYGN.

AZN Latest News Stream

Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream

Loading social stream, please wait...

View Full AZN Social Stream

AZN Price Returns

1-mo -3.05%
3-mo -0.24%
6-mo 12.26%
1-year 42.30%
3-year 103.36%
5-year 66.64%
YTD -1.93%
2019 35.58%
2018 13.77%
2017 33.10%
2016 -15.90%
2015 0.51%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9406 seconds.